Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Bloomberg High Yield Bond ETF (Symbol: JNK) where we have ...

While an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital ...

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Bloomberg High Yield Bond ETF (Symbol: JNK) where we have ...

This drug candidate comes at an opportune time as Sörensen said in the release that there is a need for a new treatment for IPF. Currently, patients with this disease only have two FDA-approved ...

Idiopathic Pulmonary Fibrosis (IPF) is a frightening, incurable disease where the lungs become increasingly damaged by scar tissue, resulting in breathing getting progressively more difficult.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Join your peers and key opinion leaders in person and take away critical insights at the only dedicated IPF meeting. Already confirmed attendees include Boehringer Ingelheim, Genentech ...

No other corporate actions details are available.

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended suspension of the idiopathic pulmonary fibrosis trial. Pliant Therapeutics will ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...